PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “IOTHALAMIC ACID”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1998

Chromatographic estimation of iothalamate and p-aminohippuric acid to measure glomerular filtration rate and effective renal plasma flow in humans.

Iothalamate (IOT) clearance and p-aminohippuric acid (PAH) clearance are used for estimation of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). A simple and rapid method is described for simultaneous determination of IOT and PAH in the same chromatogram in the serum and urine of humans. The mobile phase consisted of methanol-50 mM sodium monobasic phosphate with 0.5 mM tetrabutyl ammonium hydrogen sulfate (18:82, v/v), pumped at a rate of 0.8 ml/min on a C18 reversed-phase column. Samples of serum and urine were deproteinized with two volumes of acetonitrile containing the internal standard, p-aminobenzoic acid (PABA). The UV detector was set at 254 nm and peak height ratios of PAH or IOT to PABA were calculated with an integrator. Precision and accuracy were within 15% for both PAH and IOT. The recovery of PAH in urine and serum were 94% and 91%, respectively. For IOT the corresponding recoveries were 93% and 92%, respectively. This method clearly distinguishes acetyl-PAH from PAH and has been validated in healthy volunteers.

Adult↗
PubMed1986

Contrast, coagulation, and fibrinolysis.

Some adverse clinical effects of intravascular radiologic contrast agents have been attributed to their interference with the normal hemostatic processes. This study compares the effects of the low osmolality agents with those of the conventional agents by in vitro studies of platelet function, fibrin formation, and fibrinolytic activation. In various degrees, all the contrast agents studied inhibit platelet aggregation and fibrin formation but show virtually no direct activation of fibrinolysis. The new low osmolality agents generally show lesser inhibitory effects on the hemostatic mechanisms. Some clinical implications are discussed.

Blood Coagulation↗